Description

Edwards Lifesciences’ Hidden Growth Engine — TMTT Revenue Just Surged 44.8%!

Edwards Lifesciences reported stronger-than-expected second quarter 2026 financial results, delivering total sales growth of 12.5% year-over-year to $1.74 billion, underpinned by broad-based performance across its structural heart therapy portfolio and geographical regions. The company raised its full-year sales guidance to 10% to 11%, reflecting confidence in sustained demand and the strength of multiple growth drivers, while reaffirming its adjusted earnings per share (EPS) guidance within the prior range of $2.95 to $3.05. The transcatheter aortic valve replacement (TAVR) segment generated $1.3 billion in sales, increasing 10.5% year-over-year and benefiting from procedural growth, market expansion through new clinical evidence, and the exit of a major competitor in the prior-year quarter. Growth rates were comparable between the U.S. and international markets. Advances such as the approval of the asymptomatic indication in Japan and upcoming potential updates to U.S. National Coverage Determinations contribute to a reinforced competitive position for Edwards’ SAPIEN platform.